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Vesicular stomatitis virus (VSV) is a candidate for development for cancer therapy. We created a recombinant replicating VSV (rrVSV)
with an altered surface protein that targeted preferentially to breast cancer cells. The rrVSV genome contained a single glycoprotein (gp) gene
derived from Sindbis virus. This gene expressed a chimeric Sindbis E2 binding gp and the native Sindbis E1 fusion gp. The chimeric E2
binding gp, called Sindbis-SCA-erbb2, was modified to reduce its native binding function and to contain a single chain antibody (SCA) with
specificity for the human epidermal growth factor receptor Her2/neu protein, erbb2. These viruses selectively infected, replicated in and
killed cells expressing erbb2. The titer of rrVSV on SKBR3 cells, a human breast cancer cell line which highly expresses erbb2 was 3.1 
107/ml compared with a titer of 7.3  105/ml on 143 cells, a human osteosarcoma cell line which does not express erbb2. The titer of rrVSV
on D2F2/E2 cells, a mouse mammary cancer cell line stably transfected to express human erbb2 was 2.46  106/ml compared with a titer of
5  104/ml on the parent D2F2 cells which do not express erbb2. When titered on erbb2-negative cells, non-replicating pseudotype VSV
coated with Sindbis-SCA-erbb2 had b3% the titer of pseudotype VSV coated with wild type Sindbis gp indicating that the chimeric Sindbis
gp had severely impaired binding to the natural receptor. Analysis of the protein composition of the rrVSV found low expression of the
modified Sindbis gp on the virus.
D 2004 Elsevier Inc. All rights reserved.
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Viruses and viral vectors that kill specific cells are being
designed for cancer therapy (Ring, 2002; Russell, 1994;
Wildner, 2001; Zwiebel, 2001). Important issues are safety,
efficacy, and targeting. VSV is an excellent candidate for
development as an oncolytic virus because it is an efficient
cell killer that grows and spreads rapidly and yet is safe for
human use (de Mattos et al., 2001). VSV is endemic in
certain human populations but is not pathogenic. Wild type
(wt) VSV has eradicated established tumors in mice when
injected intratumorally or intravenously (Balachandran et al.,0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.06.048
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E-mail address: ira.bergman@chp.edu (I. Bergman).2001; Fernandez et al., 2002). Selectivity was based on the
absence of an interferon response in the tumor cells (Stojdl et
al., 2000). Safety could be further improved by restricting
the tropism of the virus.
Our goal in the present study was to create a VSV that
directly targeted to Her2/neu over-expressing breast cancer
cells. The Her2/neu receptor is an excellent target because it
is over-expressed in 25–30% of human breast cancers and is
a critical contributor to an aggressive tumor phenotype
(Slamon et al., 2001). VSV is an enveloped negative strand
RNA virus with a single surface glycoprotein (gp) called G
that fully determines binding of the virus as well as
promoting pH-dependent fusion of the virus envelope with
endosome membranes (Rose and Whitt, 2001). The receptor
for G is ubiquitous and VSV promiscuously infects most
cell types. We eliminated the G gene from the VSV genome004) 24–33
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(SV) gp. The surface gp of SV consists of an E1 fusion
protein and an E2 binding protein. Deletion of amino acids
72 and 73 within E2 reduces binding and infectivity of the
virus N90% (Dubuisson and Rice, 1993). The Sindbis gp
gene was further modified at this site to encode two
synthetic immunoglobulin G (IgG) Fc-binding domains
called ZZ derived from protein A of the Staphylococcus
aureus spa gene (Ohno et al., 1997; Morizono et al., 2001;
Sawai and Meruelo, 1998). Sindbis viruses and retroviruses
expressing this ZZ-modified gp could be targeted to specific
cells by the addition of antibody. Genetic engineering has
previously been developed to create VSV from plasmid
components (Schnell et al., 1997). We have used this
technology to create an rrVSV expressing the ZZ-modified
Sindbis gp (Bergman et al., 2003). This virus was
selectively targeted to Her2/neu amplified human breast
cancer in the presence of monoclonal antibodies directed to
the Her2/neu receptor. However, the potential use of this
virus in the clinic is limited because the titers were low and
because targeting required that a specific antibody attach to
a non-specific antibody combining site on the viral surface.
In vivo competition for this non-specific site will include the
large pool of host IgG antibodies. In addition, selective
adaptation of this virus on targeted cells was difficult
because each new generation of virus required additional
antibody to allow binding and infection of the next round of
cells. We therefore created a new chimeric SV gp gene,
called Sindbis-SCA-erbb2, by removing the gene segment
encoding ZZ and substituting a gene segment encoding for a
single chain antibody (SCA) directed to erbb2. Initially, we
synthesized non-replicating pseudotype VSV whose surface
gp was supplied in trans by a plasmid expressing the
Sindbis-SCA-erbbB2 and demonstrated selective infection
of Her2/neu expressing cancer cells. We confirmed that this
modification of the Sindbis E1 gp reduced non-specific
binding N90% compared to wt Sindbis gp. We then
substituted this gene within the VSV genome in place of
the G gene and created replicating VSV whose only surface
gp was Sindbis-SCA-erbb2. This rrVSV selectively infected
Her2/neu expressing cancer cells.Fig. 1. Titer on two pairs of cell lines of non-replicating VSV-EGFP-DG.
SKBR3 and D2F2/E2 are cell lines that express erbb2. 143 and D2F2 are
cell lines that do not express erbb2. Mean of three experiments with
standard error bars. (A) Titer of pseudotype VSV-EGFP-DG coated with wt
Sindbis gp. (B) Titer of pseudotype VSV-EGFP-DG coated with Sindbis-
SCA-erbb2 gp.Results
Non-replicating pseudotype VSV coated with
Sindbis-SCA-erbb2 gp specifically infects Her2/neu
over-expressing cells
Our goal was to develop VSV for clinical use in cancer
therapy by restricting its tropism to cells that over-express
the Her2/neu receptor. To this end, a recombinant VSV
(rVSV) genome was constructed in which the G gene was
replaced by a gene encoding green fluorescent protein
(EGFP-DG/XN2). This construct was used to create a non-
replicating virus whose genome consisted of rVSV-EGFP-DG and whose surface protein, supplied in trans by
transfection, was either Sindbis-SCA-erbb2 or wt Sindbis
gp. Titers of these viruses were easily determined by
infecting a target cell line and counting green cells 1 day
later. Titers were determined on two pairs of cell lines,
SKBR3 versus 143 cells and D2F2/E2 versus D2F2 cells.
SKBR3 is a human breast cancer line that highly expresses
Her2/neu and 143 is a human osteosarcoma cell line that
does not express Her2/neu. D2F2/E2 is a mouse mammary
cancer cell line that has been stably transfected with a
plasmid expressing human Her2/neu and D2F2 is the parent
cell line. Infection with pseudotype rVSV-EGFP-DG coated
with wt Sindbis gp showed no specificity for Her2/neu
expressing cells and yielded similar titers in both cell lines
from each pair (Fig. 1A). On the other hand, pseudotype
rVSV-EGFP-DG coated with Sindbis-SCA-erbb2 gp
showed a greater than 10-fold better titer on the cell line
in each pair that expressed Her2/neu (Fig. 1B). Incubation of
the virus in the presence of Herceptin, an antibody directed
to the erbb2 receptor on the cell surface, reduced titer on
D2F2/E2, the cell line expressing erbb2 but had no effect on
titer on D2F2, the parent cell line that did not express erbb2
(Fig. 2). Inhibition was antibody dose-dependent and
Fig. 3. Titer on two pairs of cell lines of replicating recombinant VSV-SCA-
erbb2. SKBR3 and D2F2/E2 are cell lines that express erbb2. 143 and
D2F2 are cell lines that do not express erbb2. Mean of three experiments
with standard error bars.
Fig. 2. Inhibition by anti-erbb2 MAb, Herceptin, of titer of pseudotype VSV coated with Sindbis-SCA-erbb2 gp on D2F2 and D2F2/E2 cells. Mean of two
experiments with SE bars. X-axis is log2 scale.
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concentration of 20 Ag/ml. An irrelevant antibody control
had no effect. Inhibition by anti-erbb2 antibody may have
been incomplete because, as suggested by others, the virus
with multiple binding sites may have higher avidity for the
receptor than the antibody (Martin et al., 2003). Also these
antibodies bind to the cellular receptor and not to the virus
and are therefore not directly neutralizing for the virus.
Titer of the pseudotype rVSV-EGFP-DG coated with
Sindbis-SCA-erbB2 gp was higher on the SKBR3 cells
than the D2F2/E2 cells. One possible explanation was that
SKBR3 cells expressed higher amounts of erbb2 on the
cell surface than D2F2/E2 cells, as demonstrated by flow
cytometry. The mean fluorescence on cells stained with the
humanized anti-erbb2 monoclonal antibody Herceptin was
401 on SKBR3 cells, 186 on D2F2/E2 cells, and 12 on
D2F2 cells. When titered on erbb2-negative cells, non-
replicating pseudotype VSV coated with Sindbis-SCA-
erbb2 had b3% the titer of pseudotype VSV coated with
wild type Sindbis gp indicating that the chimeric Sindbis
gp had severely impaired binding to the natural receptors
(Figs. 1A–B). We have previously demonstrated that the
baseline titer of control VSV-EGFP-DG created without a
surface gp was very low (b103/ml) and presumably
represented residual inoculum virus used in the producer
cells to create these various pseudotypes (Bergman et al.,
2003).
Replicating recombinant VSV (rrVSV) expressing
Sindbis-SCA-erbb2 specifically infects Her2/neu
over-expressing cells
Once we knew that Sindbis-SCA-erbbB2 gp targeted to
the Her2/neu receptor, we constructed a recombinant VSV
(rVSV) genome in which the G gene was replaced by agene encoding Sindbis-SCA-erbb2 as well as a separate
gene encoding green fluorescent protein (Sindbis-SCA-
erbb2-EGFP-DG/XN2). A replication-competent VSV
virus was created from this genome, which contained the
gene expressing Sindbis-SCA-erbb2 in the viral genome
and whose only coat proteins were the Sindbis derived E1
and Sindbis-SCA-erbb2 gp. This virus was called rrVSV-
Sindbis-SCA-erbb2 and showed targeted infection of Her2/
neu expressing SKBR3 and D2F2/E2 cells (Fig. 3). The
titer of the rrVSV was N40-fold better on the cell line in
each pair that expressed Her2/neu. Two color flow
cytometric analysis demonstrated that when rrVSV
expressing Sindbis-SCA-erbb2 was incubated with a mixed
culture of SKBR3 and 143, 25% of the Her2/neu over-
expressing SKBR3 were infected compared with 2.5% of
the 143 cells (Fig. 4). In addition to specific targeting,
rrVSV-expressing Sindbis-SCA-erbb2 also displayed spe-
Fig. 4. (A) Two color flow cytometric analysis of a mixture of SKBR3 and
143 cells 8 h after infection at MOI = 1 with rrVSV expressing Sindbis-
SCA-erbb2. Cells were stained with the anti-erbb2 MAb 4D5 followed by a
R-Phycoerythrin-conjugated goat anti-mouse IgG antibody. Infected cells
are positive for FL1-fitc (right quadrants) because the virus expresses
EGFP. Erbb2 over-expressing cells are positive for FL2-PE (upper
quadrants). Infected cells that are also erbb2 over-expressing are found in
the upper right quadrant. The percentage of total cells in each quadrant is
listed in that quadrant. (B) Control plot of an uninfected mixture of SKBR3
and 143 cells stained with the anti-erbb2 MAb 4D5. Erbb2 over-expressing
cells are positive for FL2-PE (upper left quadrant).
Fig. 5. Growth of replicating recombinant VSV-SCA-erbb2 in SKBR3 cells
that express erbb2 and 143 cells that do not.
Fig. 6. Inhibition by 30 nM of Bafilomycin A1 of titer on SKBR3 cells of
pseudotype VSV-EGFP-DG coated with either VSV-G, wt Sindbis or
Sindbis-SCA-erbb2. Mean of three experiments with standard error bars.
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cells. The cytopathic effect of rrVSV was measured in
cells that did and did not express Her2/neu and based on
trypan blue exclusion 1 day after infection at MOI = 0.5
was 92.1% in SKBR3 cells and 7.7% in 143 cells.
Stability and concentration of viral particles
In the future, clinical applications of this virus may
require concentration and storage. rrVSV was reasonably
stable to freeze/thaw. Two freeze/thaw cycles of the virus
produced a 21% loss of titer for wt VSV and a 39% loss of
titer for rrVSV expressing Sindbis-SCA-erbb2. rrVSV
expressing Sindbis-SCA-erbb2 could be easily concentrated
40 fold by filtration (Centricon-Plus-20 Centrifugal Filter
Device with Biomax membrane, 100 K NMWL, Millipore
Corp., Billerica, MA). Further concentration was notattempted. Filtration concentrated the virus from 36 ml
with a titer of 1.44  106/ml to 0.5 ml with a titer of 5.7 
107/ml. Recovery rate was 55%.
Endosomal pH dependence
We sought to determine whether rrVSV with a new
attachment protein would still enter its target cells via the
endosome. Bafilomycin A1, a macrolide antibiotic, is a
specific inhibitor of vacuolar-type H+-ATPase that blocks
acidification of the endosome. Titers on Her2/neu over-
expressing SKBR3 cells of pseudotype VSV coated with
either wt VSV-G gp, wt Sindbis gp or recombinant Sindbis-
SCA-erbb2 gp were determined in the presence of Bafilo-
mycin, 30 nM. Bafilomycin blocked N99% of infection with
all three viruses indicating that viral entry of the rrVSV was
endosomal-dependent (Fig. 6). We have previously shown
that this concentration of Bafilomycin did not inhibit
infectivity of a pseudotype VSV coated with the F and
HN gp of SV5 virus which entered the cell by direct fusion
with the cell membrane (Bergman et al., 2003).
Protein composition of the recombinant viruses
We performed SDS-PAGE analysis of 35S-methionine
radiolabeled pseudotype and replicating recombinant viruses
to confirm incorporation of the expected proteins into each
Fig. 8. SDS-PAGE analysis of cell extracts prepared at various times
following infection of D2F2/E2 cells with rrVSV expressing Sindbis-SCA-
erbb2. Cells were metabolically labeled with 35S-methionine. The wt VSV
proteins are used as molecular weight markers.
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proteins M, N, P, and L. The yield of pseudotype viruses is
lower than rrVSV in part because we could achieve higher
titers of replicating than pseudotype viruses (Figs. 1 and 3)
and in part because the radiolabeling conditions required
more extensive purification of the pseudotype than the
replicating viruses. Nonetheless, all the VSV proteins except
for P are clearly visible. Most importantly, the rrVSV
contain the expected Sindbis E1 and modified Sindbis E2 gp
and do not contain VSV G gp. Comparison of viruses
expressing wt Sindbis E2, Sindbis E2 modified to express
ZZ and Sindbis E2 modified to express SCA-erbb2 shows
the expected higher migration of the E2 protein as larger
inserts are added to the gene. Sindbis-ZZ adds 0.438 kb
coding for two synthetic immunoglobulin G (IgG) Fc-
binding domains, whereas Sindbis-SCA-erbb2 adds 0.867
kb coding for the SCA and linkers. The unmodified E1 band
remains the same size in the three viruses. Protein analysis
of the rrVSV demonstrates poor incorporation of modified
Sindbis glycoprotein into the rrVSV particles compared with
wt VSV particles (Fig. 7). The difference in labeling
intensity is not an artifact of amino acid composition
because the number of methionine amino acids in VSV-G,
Sindbis E1 and Sindbis E2 are similar. Possible explanations
for the difference include variations in gp synthesis, trans-
port or viral incorporation. Fig. 7 demonstrates that wt
Sindbis and Sindbis-ZZ gp incorporation into virus were
better when virus was prepared at 32 than 37 8C, suggesting
a problem in protein transport. Incorporation of Sindbis-
SCA-erbb2 was not temperature-dependent but was poor in
the replicating virus and not visible in the pseudotype virus.
A block in protein trafficking that is not relieved at lowerFig. 7. SDS-PAGE analysis of pseudotype and replicating recombinant viruses. V
VSV and rrVSV were grown in SKBR3 cells. Pseudotypes were made in BHK 21
(Lanes marked B). The wt VSV proteins are used as molecular weight (MW) ma
phosphorylated. The lanes contain the following viruses: (1) rrVSVexpressing Sin
synthetic immunoglobulin G (IgG) Fc-binding domains. (2) rrVSVexpressing Sind
for the SCA and linkers. (3) wt VSV. (4) Pseudotype VSVexpressing Sindbis-ZZ, a
immunoglobulin G (IgG) Fc-binding domains. (5) Pseudotype VSVexpressing wt
modified Sindbis gp with the addition of 0.867 kb coding for the SCA and linketemperature may explain the poor incorporation of Sindbis-
SCA-erbb2. To examine modified Sindbis gp synthesis, we
performed SDS-PAGE analysis of cell extracts prepared at
various times following infection of D2F2/E2 cells with
rrVSV expressing Sindbis-SCA-erbb2 (Fig. 8). The modi-
fied E2 gp was synthesized appropriately, and as expected,
there are two bands for the gp with the slightly larger band
representing a precursor protein. Purified virus, as shown in
Fig. 7, contains only the lower band. Cell lysate from virusiruses were prepared in cells metabolically labeled with 35S-methionine. wt
cells. Each virus was prepared at either 32 8C (Lanes marked A) or 37 8C
rkers. VSV P protein migrates larger than its calculated MW because it is
dbis-ZZ, a modified Sindbis gp with the addition of 0.438 kb coding for two
bis-SCA-erbb2, a modified Sindbis gp with the addition of 0.867 kb coding
modified Sindbis gp with the addition of 0.438 kb coding for two synthetic
Sindbis glycoprotein. (6) Pseudotype VSVexpressing Sindbis-SCA-erbb2, a
rs. (7) wt VSV.
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ml, (Cat. No. 2076KK, BD Biosciences) contains only the
upper band because processing through the Golgi is
interrupted (data not shown) (Sariola et al., 1995; Watson
et al., 1991).Discussion
We have demonstrated the ability to create an autono-
mous replicating VSV virus that is targeted to specific
cancer cells by a single chain antibody expressed on the
viral surface. rrVSV were made whose genome possessed a
gp gene that was a modified Sindbis gp cassette containing
an SCA directed to erbb2. Sindbis gp was utilized because
previous work had identified a site in which a new protein
domain could be inserted that would be functional and also
impair native Sindbis binding (Dubuisson and Rice, 1993;
Ohno et al., 1997). A similar site in the VSV G gene has
not been discovered. This new rrVSV expressing Sindbis-
SCA-erbb2 selectively infected cancer cells expressing the
Her2/neu receptor protein achieving titers of 3.1  107/ml.
Previous reports have used SCA to target retroviruses,
adeno-associated virus (AAV) and attenuated measles virus
(MV). For retroviruses and AAV, titers at best were only
about 1  105/ml (Jiang et al., 1998; Khare et al., 2001;
Marin et al., 1996; Martin et al., 2003; Yang et al., 1998).
The SCA gene was not incorporated into the retroviral
genome and the viruses could not replicate. These viruses
cannot be used directly to kill tumor cells because they are
not cytolytic. For MV, the titers against specific cells were
6  104–6  105/ml and native MV binding was not at all
attenuated. Rather, the tropism of the virus was extended to
cells not normally infected by MV. Unlike retroviruses,
however, these targeted MV were replication competent
and cytolytic (Bucheit et al., 2003; Hammond et al., 2001;
Peng et al., 2003). The present rrVSV particle grew to titers
of 107/ml, was stable to freeze/thaw and could be
concentrated. Cell entry was endosome-dependent. These
findings are consistent with previous work, which demon-
strated that VSV is able to form viable virus using foreign
gp. Studies showed efficient budding of recombinant VSV
expressing chimeric G proteins with the transmembrane
and cytoplasmic domains derived from the human CD4
protein (Schnell et al., 1996). A cytoplasmic domain of at
least 9 amino acids was required but there was no
requirement for a specific sequence in that domain (Schnell
et al., 1998).
Analysis of the protein composition of rrVSV demon-
strated much lower concentration of gp than that found in wt
VSV. Possible explanations for the difference include
variations in gp synthesis, transport or viral incorporation.
Sindbis-SCA-erbb2 gp is a synthetic chimeric protein with
no natural counterpart that may not traffic easily through the
cellular endoplasmic reticulum and Golgi apparatus to the
plasma membrane and may not be efficiently incorporatedinto the viral envelope. Similar results have previously been
reported for an SCA-retroviral surface protein chimera
(Martin et al., 2003). We intend to explore the reasons for
poor incorporation in future work. Understanding this
failure may suggest further modifications of the chimeric
protein that will improve its ability to incorporate into the
viral particle and yield higher titers on selected cancer cells.
rrVSV expressing Sindbis-SCA-erbb2 retained a small
degree of infectivity against cells that did not express Her2/
neu indicating that not all of the native Sindbis binding
function had been eliminated. Further work is necessary to
disable this residual non-specific binding. Several inves-
tigators have identified areas of the E2 gp that may represent
binding domains (Phinney et al., 2000; Smith et al., 1995;
Zhang et al., 2002). We have created an ideal means of
testing the functional effects of mutations in these areas. We
have a functional modified Sindbis E2 whose binding is in
large part determined by an SCA. We can test whether a site
is important for native Sindbis binding by mutating it and
comparing infectivity in erbb2-positive and -negative cell
lines. Without this capability, abolishing native binding
would create a virus that could not be detected. One would
have great difficulty distinguishing a mutation that selec-
tively involved binding function from one that created a
dysfunctional protein that did not traffic appropriately
through the cell.
This study demonstrates the ability to easily create,
directly from plasmid components, an oncolytic replicating
adapting VSV with a restricted host cell range. We are
testing this virus in the treatment of transplantable mouse
tumors that express human her2/neu. The methodology and
vector design allows easy substitution of genes expressing
other SCA or binding proteins within the VSV genome to
create rrVSV with a wide variety of specificities. VSV is an
excellent candidate for development as an oncolytic virus
because of its potency, safety and ability to be engineered.Materials and methods
Cells, antibodies and chemicals
The following cell lines were obtained from American
Type Culture Collection (ATCC) (Rockville, MD) and
grown using standard tissue culture techniques in a
humidified incubator at 37 8C with 5% CO2: SKBR3
human breast adenocarcinoma, 143 human osteosarcoma,
COS-7 simian kidney and BHK 21 hamster kidney. SKBR3
cells are known Her2/neu amplified/over-expressing breast
cancer cells whereas 143 do not express measurable Her2/
neu (Bergman et al., 2001). D2F2/E2 is a mouse mammary
tumor line that has been stably transfected with a vector
expressing the human Her2/neu gene and was a generous
gift from Dr. Wei-Zen Wei, Karmanos Cancer Institute,
Wayne State University, Detroit, MI. D2F2 is the parent
mouse mammary tumor cell line. Absence of mycoplasma
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Probe rapid detection system (Gen-Probe Incorp., San
Diego, CA). MAb 4D5, a mouse monoclonal antibody
directed to the Her2/neu receptor was provided by Gen-
entech, Inc. (San Francisco, CA). Herceptin, the humanized
form of 4D5 was obtained from Genentech. Bafilomycin A1
was obtained from Kamiya Biomedical Co. (Seattle, WA).
Flow cytometry
SKBR3 cells, 4  105/well, and 143 cells, 2  105/well,
were plated simultaneously in individual wells of 6 well
tissue culture trays (Corning Inc., Cat# 3516, Corning, NY).
These cell numbers were chosen because we knew from
previous experience that in 24 h, the wells would be nearly
confluent with about equal numbers of adherent cells of the
two cell lines. Cells were infected with rrVSV expressing
Sindbis-SCA-erbb2 at MOI = 1 and harvested 8 h later. Cells
were analyzed 8 h after infection before many infected cells
expressed green fluorescence because at later times cell death
interfered with interpretation of the assay. Flow cytometry
was performed by incubating the cells with 100 Al of anti-
erbb2 MAb 4D5 and then staining with a R-Phycoerythrin-
conjugated goat anti-mouse IgG antibody (Sigma P9670, St.
Louis, MO). Immunofluorescence was quantified using a
FACStarPlus cytometer (Becton Dickinson, Mountainview,
CA). All cells were included in the analysis.
Vectors, VSV pseudotypes and recombinant VSV genomes
Vectors expressing the VSV genome (XN2) and the
individual VSV genes P, L, N and G (pBS-P, L, N and G,
respectively) on a T7 promoter were a very generous gift of
Dr. John K. Rose, Yale University School of Medicine. A
vector expressing VSV-G on a CMV promoter (CMV-VSV-
G) was a generous gift of Dr. Paul D. Robbins, University of
Pittsburgh School of Medicine. Vectors expressing Sindbis
gp (Sindbis) and Sindbis gp modified between amino acids
71 and 74 to express two IgG binding domains (Sindbis-ZZ)
were generously supplied by Dr. Irvin S. Y. Chen,
University of California, Los Angeles Medical School. We
replaced the ZZ IgG binding domain with a gene coding for
an SCA to erbb2 as follows. A vector expressing an SCA
based on the 4D5 anti-erbb2 antibody was a generous gift
by Genentech Inc. The gene segment coding for the mature
structural protein without the signal sequence was amplified
with a series of primers to produce the following construct:
ggtaacc(BstE II) agctcaggtggaggcggttcaggcggaggtg-
gctctggcggtggcg gatctgctagc (Nhe 1)-mature SCA-erbB2-
atcgat(Cla 1) gctaaaacgaccgcaccgtcctgtctac ccactgg-
cacctgtctcgtctggatccgggtctctggtaacc (BstE II). Preceding
the mature SCA, between the BstEII and Nhe1 restriction
sites we placed a flexible poly-glycine linker. Following the
mature SCA between the Cla1 and BstEII restriction sites,
we placed a spacer adapted from Jost et al. (1996) and
consisting of the first 13 amino acids of the CH1 region ofthe 2C11 hamster monoclonal antibody and a flexible
serine–glycine end. This construct now replaced ZZ
between amino acids 71 and 74 of the Sindbis gp to create
a chimeric Sindbis gp which consisted of the first 71 amino
acids of E2 followed in order by a poly-glycine linker, SCA
to erbb2, CH1 linker, the remainder of the E2 Sindbis gp
and the entire E1 Sindbis gp. This construct was called
Sindbis-SCA-erbb2. It was designed so that the specific
SCA-erbb2 in this construct could easily be replaced with
any other SCA by digesting and ligating at the Nhe1 and
Cla1 sites.
The Sindbis-SCA-erbbB2 construct expressed through a
CMV promoter was used to create VSV pseudotypes as
previously described (Bergman et al., 2003). In brief, we first
constructed a recombinant VSV (rVSV) genome in which
the G gene was replaced by a gene encoding green
fluorescent protein (EGFP-DG/XN2). This construct was
used to create a non-replicating virus whose genome
consisted of rVSV-EGFP-DG and whose surface protein
was G as follows (Lawson et al., 1995). EGFP-DG/XN2,
pBS-P, pBS-L, pBS-N, and pBS-G were transfected into
COS-7 cells and infected at MOI = 6 with vTF-7, a vaccinia
virus expressing T7 polymerase (NIH AIDS research and
reference reagent program, Rockville, MD). Virus were
harvested from the supernatant 2 days later and amplified on
BHK 21 cells that were transfected with CMV-VSV-G using
a standard lipofectamine protocol. Non-replicating pseudo-
type VSV were created by transfecting BHK 21 with DNA
encoding either Sindbis gp or Sindbis-SCA-erbb2 gp and 2
days later infecting with rVSV-EGFP-DG at an MOI of 6.
Supernatant was harvested 1 day following infection and
stored at 70 8C. All pseudotype viruses, therefore, used in
this report were made in BHK 21 cells. Titers were
determined by adsorbing the virus at different dilutions on
the indicator cell line in wells of a 6-well tray (Corning Inc.)
for 2 h, washing and replacing the media. Green cells were
counted in an inverted fluorescent microscope (Axiovert
135, Carl Zeiss, Inc., Thornwood, NY) 1 day later. Inhibition
of viral titer by antibody to erbb2 was determined by
incubating cells at 4 8C first with antibody for 30 min and
then with virus and antibody for 60 min. This temperature
was chosen to prevent antibody capping and endocytosis into
the cell. The cells were then incubated overnight at 37 8C and
the titer measured at 24h. The percent inhibition was 1 
(titer with antibody) / (titer without antibody)  100.
Similar techniques were used to create a recombinant
replicating VSV whose surface gp was Sindbis-SCA-erbb2.
First, the gene for Sindbis-SCA-erbb2 was digested from the
vector supplied by Dr. Irvin S. Y. Chen and inserted into the
recombinant VSV genome, EGFP-DG/XN2, between the
genes for VSV-M and EGFP. This was accomplished by
using primers to add a multiple cloning site containing Not1
and Pme1 restriction sites and VSV transcription stop and
start signals (italics) in front of the gene for EGFP as follows:
acgcgt (Mlu 1)cgtacggtaacctcgagaaagcggccgc (Not1)gc-
gcgtttaaac (Pme1) tatgaaaaaaactaacagagatccact. The
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Not1 and Pme1 restriction sites. In addition, for the purpose
of our future in vivo studies, the gene for mouse GM-CSF
was added at the Mlu 1 site by using primers to add an Mlu 1
site in front of the GM-CSF gene and stop and start signals
followed by an Mlu 1 site at the end of the gene. This
recombinant VSV genome was called mGMCSF-Sindbis-
SCA-erbb2-EGFP-DG/XN2 (Fig. 9). This new recombinant
genome as well as pBS-P, pBS-L, pBS-N and pBS-G were
transfected into COS-7 cells and infected with vTF-7. The
pBS-G vector was included to make a virus that contained
VSV-G on its surface and could be amplified on BHK 21
cells. Virus were harvested from the supernatant 2 days later
and amplified on BHK 21 cells that were transfected with
CMV-VSV-G, a vector that expresses wt VSV G protein.
Viral stocks were made from virus grown in unmodified
SKBR3 or D2F2/E2 cells and titered in the same cell lines.
All replicating viruses used in this report were made in
SKBR3 cells except the virus titered on D2F2/E2 which was
grown on D2F2/E2. Viral RNAwas harvested, converted to
cDNA using RT-PCR and sequenced to prove that the gene
for Sindbis-SCA-erbb2 was appropriately placed in the VSV
genome. Because the gene for VSV G was deleted from the
genome, the only surface gp on this virus was Sindbis-SCA-
erbb2. Titers were determined as detailed above except that
after 2 h of viral adsorption the media was replaced with
media containing 30 nM Bafilomycin A1 to avoid counting
newly produced virus.
Growth of replicating virus was determined by adsorb-
ing the virus at MOI = 0.005 for 2 h on the indicator cell
line, plated at 2  105 cells in one well of a 6 well tray,
washing three times, replacing the media and counting
green cells in an inverted fluorescent microscope every 6 h
for 24 h. The number of infected cells could not be
accurately counted after this time because of cell clumping
and lysis of early infected cells. Cytopathic effect (CPE)
was determined by adsorbing the virus on the indicator cell
line in one well of a 6-well tray at MOI = 10 for 2 h,
washing, replacing the media and harvesting all cells after
1 day. The number of live cells in the virus infected well
was divided by the number of live cells in a no virus
control well and multiplied by 100 to determine the
percentage of living cells following treatment. The percent
CPE was 100 minus this number.
Analysis of the protein composition of pseudotype and
replicating VSV and infected cells
Preparation of 35S-labeled virus was performed as
previously described with modifications (Whitaker-Dow-Fig. 9. Gene structure in rrVSV expressing Siling et al., 1983). VSV pseudotypes were created by
transfecting BHK 21 with DNA encoding either Sindbis
gp or Sindbis-SCA-erbb2 gp. Twenty-four hours after
transfection, the media was removed from each well and
replaced with 1 ml of cysteine/methionine free media
(Cat# 19050-121, Gibco/BRL,) containing 20 ACi/ml of
35S-methionine (Trans35S-LABEL, 10 mCi/ml, ICN Bio-
chemicals, Irvine, CA, Cat# 51006). Forty-eight hours
after transfection, the cells were infected by the addition
of VSV-EGFP-DG coated with G gp at a multiplicity of
infection (MOI) of 5. After a 2-h adsorption period, the
inoculum was removed and the cells refed with 1 ml of
cysteine/methionine-free media containing 20 ACi/ml of
35S-methionine. Seventy-two hours after transfection, the
media containing the radiolabeled virus was harvested,
and the cell debris removed by centrifugation at 1000 
g for 5 min. The virus in the supernatant was then
pelleted by ultracentrifugation in a swinging bucket rotor
at 80,000  g for 2 h. The virus pellets were resuspended
in 200 Al of complete medium and layered on a 10% to
40% sucrose gradient containing 10 mM Tris pH 7.4, 1
M NaCl, and 1 mM EDTA. The gradient was subjected
to ultracentrifugation in a swinging bucket rotor at 35,000 
g for 90 min. The radiolabeled viral band was collected
and diluted to 33 ml with serum-free medium and
repelleted by ultracentrifugation as described. The virus
pellet was resuspended in 200 Al of serum-free medium.
The purified radiolabeled virus was diluted 1:1 with 2
Laemmli sample buffer and subjected to analysis by
sodium dodecyl sulfate polyacrylamide gel electrophoresis
using 10% acrylamide containing 0.09% bis acrylamide.
The gel was dried under vacuum and examined by
autoradiography. Viral bands were identified by their
molecular weights. Viral yield following this extensive
purification was low accounting, in part, for the inability
to visualize the VSV P protein. Similar techniques were
used to prepare 35S-labeled recombinant replicating VSV
whose surface gp was Sindbis-SCA-erbb2 or wt VSV G.
Two hours after infection of SKBR3 cells in individual
wells of a 6-well tissue culture tray (Corning Inc.) with
either wt VSV or rrVSV at MOI = 6, the media was
removed and replaced with 1 ml of cysteine/methionine
free media containing 20 ACi/ml of 35S-methionine. The
media containing the radiolabeled virus was harvested 24
h after infection and the cell debris removed by
centrifugation at 1000  g for 5 min. The virus in the
supernatant was then pelleted and subjected to gel
electrophoresis as above. Analysis of cellular proteins
following viral infection was performed by infecting
D2F2/E2 cells in individual wells of a 6 well tissuendbis-SCA-erbb2 (not drawn to scale).
I. Bergman et al. / Virology 330 (2004) 24–3332culture tray with rrVSV at MOI = 1. At various times,
individual wells were labeled for 2 h with 35S-methionine
as above. The cell layer was then lysed in 2 Laemmli
sample buffer and subjected to gel electrophoresis.Acknowledgments
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